The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer.
A sensitive flow cytometric assay has been developed using a monoclonal antibody, Myc 1-6E10, to quantitate c-myc oncoprotein levels in nuclei isolated from wax embedded testicular tumours. The oncoprotein (p62c-myc) level increased significantly with increasing teratoma differentiation. Patients with intermediate and undifferentiated tumours who developed recurrence had lower p62c-myc levels than those who were disease free since their initial treatment. Such quantitative biochemical methods may provide new prognostic indices for cancer patients.
D000911:Antibodies, Monoclonal; D002471:Cell Transformation, Neoplastic; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D009857:Oncogenes; D011379:Prognosis; D014176:Protein Biosynthesis; D012008:Recurrence; D013724:Teratoma / Q000235:genetics / Q000378:metabolism; D013736:Testicular Neoplasms / Q000235:genetics / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D009363:Neoplasm Proteins